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Studies in preclinical models have demonstrated the superior anti-tumor effect of CpG oligodeoxynucleotides (CpG-ODN) when
administered at the tumor site rather than systemically. We evaluated the effect of aerosolized CpG-ODN on lung metastases
in mice injected with immunogenic N202.1A mammary carcinoma cells or weakly immunogenic B16 melanoma cells. Upon
reaching the bronchoalveolar space, aerosolized CpG-ODN activated a local immune response, as indicated by production of
IL-12p40, IFN-c and IL-1b and by recruitment and maturation of DC cells in bronchoalveolar lavage fluid of mice. Treatment
with aerosolized CpG-ODN induced an expansion of CD41 cells in lung and was more efficacious than systemic i.p. adminis-
tration against experimental lung metastases of immunogenic N202.1A mammary carcinoma cells, whereas only i.p. delivery
of CpG-ODN provided anti-tumor activity, which correlated with NK cell expansion in the lung, against lung metastases of the
poorly immunogenic B16 melanoma. The inefficacy of aerosol therapy to induce NK expansion was related to the presence of
immunosuppressive macrophages in B16 tumor-bearing lungs, as mice depleted of these cells by clodronate treatment
responded to aerosol CpG-ODN through expansion of the NK cell population and significantly reduced numbers of lung metas-
tases. Our results indicate that tumor immunogenicity and the tumor-induced immunosuppressive environment are critical fac-
tors to the success of CpG therapy in the lung, and point to the value of routine sampling of the lung immune environment in
defining an optimal immunotherapeutic strategy.
Synthetic oligodeoxynucleotides containing dinucleotides with
unmethylated CpG motifs (CpG-ODN), agonists of TLR9,
represent a novel approach to stimulating an effective
anti-tumor response as demonstrated in preclinical models1
and in patients with malignant melanoma, renal carcinoma
and recurrent or refractory lymphoma.1,2 However, efﬁcacy
of CpG in the lung, where virtually continuous exposure to
environmental antigens dictates local immunological homeo-
stasis and the meticulous control of immune responses, has
been limited to the control of lung metastatic growth only
when administered before tumor cell injection or immedi-
ately after when disease is minimal in various preclinical tu-
mor models.3–5 Although a randomized Phase II trial with
non-small lung cancer patients showed promising results and
led to two large randomized Phase III trials comparing CpG-
ODN plus chemotherapy to chemotherapy alone, interim
analysis of those trials did not support the promise of CpG-
ODN in enhancing the efﬁcacy of chemotherapy and caused
the suspension of the trials.2 Several studies have suggested
that the route of administration is a critical factor in inﬂu-
encing CpG activity. The anti-tumor effect of CpG has been
optimized by direct injection into the tumor to enable
increased local concentrations in the tumor microenviron-
ment and to ensure effective local activation of both innate
and adaptive immune responses.6–9
Thus, local instead of systemic administration of the TLR9
agonist might represent an option to improve the efﬁcacy of
CpG as adjuvant in protecting against lung cancer or in
treating and/or preventing lung metastases derived from dif-
ferent primary tumors. Bronchial and bronchoalveolar
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tumors are accessible via the endobronchial space. To date,
CpG-ODN has been delivered to the lung intranasally (i.n.)
in different preclinical studies that document its adjuvant
activity and therapeutic potential in the treatment of airway
pathogen infections and in asthma models.10–12 The immu-
nomodulatory effects triggered locally in the lung by CpG-
ODN through this route have recently been well studied to
clarify the mechanisms involved in the CpG-linked adjuvan-
ticity.13 Although this route is not practical in the clinical set-
ting, an inhaler/nebulizer represents a more convenient and
simpler approach for repeated application, ensuring a more
uniform distribution and penetration into the alveolar region
of the lung. Aerosol administration to deliver therapeutic
agents locoregionally, including gene delivery of mitogen-
activated protein kinase Kinase 4,14 PTEN,15 interleukin-12,16
interleukin-2,17 granulocyte/macrophage colony-stimulating
factor18 and p53,19 and delivery of chemotherapeutic agents,
such as gemcitabine20 and docetaxel combined with cele-
coxib,21 and antisense oligonucleotides alone or in combina-
tion with anticancer drugs,22,23 have also been tested in mice
with lung cancer, and a Phase I clinical trial with aerosolized
liposomal 9-nitro-20 (S)-camptothecin in lung cancer patients
has been performed.24 Overall, these studies indicate that
aerosolized pulmonary delivery allows wide localization of
these agents in the bronchiolar epithelium, alveolar epithe-
lium and endothelium and, as compared to systemic admin-
istration, provides better retention of the different agents in
the lungs while minimizing their penetration into the
systemic circulation, thus limiting adverse side effects.
Herein, we evaluated the ability of aerosol-delivered CpG-
ODN to activate immune cells in the lung and its efﬁcacy in
treating established malignant lung lesions in two different
murine tumors, the immunogenic mammary carcinoma
N202.1A expressing the rat neu oncogene, and the poorly
immunogenic B16 melanoma in which protection is mainly
mediated by innate effectors.
Material and Methods
Cell lines and reagents
N202.1A cells, derived from a spontaneous mammary carci-
noma in an FVB-neuN transgenic mouse,25 and B16 mouse
melanoma cells were routinely maintained at 37C in a 5%
CO2 atmosphere in Roswell Park Memorial Institute medium
1640 and Dulbecco’s modiﬁed Eagle’s Medium, respectively,
supplemented with 10% fetal calf serum and 2 mM gluta-
mine. Puriﬁed, phosphorothioated ODN1826 (50-TCCAT-
GACGTT CCTGACGTT-30) containing CpG motifs was
synthesized by TriLink Biotechnologies (San Diego, CA).
Mice and experimental protocols
All experiments were carried out using 8- to 12-week-old
female FVB and C57BL/6 mice (Charles River, Calco, Italy)
maintained in laminar-ﬂow rooms at constant temperature
and humidity, with food and water given ad libitum. Experi-
ments were approved by the Ethics Committee for Animal
Experimentation of the Fondazione IRCCS Istituto Nazionale
dei Tumori of Milan according to institutional guidelines.
Aerosol administration was performed using a mouse
whole-body exposure system consisting of an AeronebVR Lab
Micropump Nebulizer that generates aerosol into a plastic
box with a sealed top and a wire netting ﬂoor that contains
up to 10 mice (EMMS Unit 32 Bordon, Hants, UK). CpG-
ODN was dissolved in 5 ml saline and placed in the nebu-
lizer unit. The aerosolized solution was introduced into the
box via a accordion tube at a short distance from the nebu-
lizer at one end and discharged at the other end. Mice were
exposed to aerosol for 15 min, with the 5-ml volume of liq-
uid in the nebulizer nearly consumed in 10 min. Control
mice received aerosolized saline. Intraperitoneal (i.p.) admin-
istration was performed as described6 using 20 mg CpG ODN
in 200 ml saline/mouse. FVB or C57BL/6 mice were injected
intravenously (i.v.) with 3 3 105 N202.1A carcinoma cells or
5 3 105 B16 melanoma cells, respectively, and treated 72 hr
later with aerosol (1.5 or 2.5 mg) or i.p. CpG-ODN adminis-
tered at 72- to 96-hr intervals for 3 weeks. Control mice were
injected with tumor cells only. All mice were anesthetized
and euthanized 5 weeks after tumor injection, and macro-
scopic lung metastases were counted. In each experiment,
mice were weighed twice weekly.
Depletion of macrophages with clodronate
Clodronate-loaded liposomes or control PBS-liposomes were
prepared as described26 and injected (100 ml) intratracheally
(i.t.) into anesthetized mice 96 hr after i.v. injection of 5 3
105 B16 melanoma cells. After 24 hr (120 hr after tumor
injection), mice were treated with aerosol or i.p. CpG-ODN 4
days/week for 2 or 4 weeks in experiments to evaluate lung
inﬁltrate or protection from tumor growth, respectively. In
What’s new?
CpG oligodeoxynucleotides (CpG-ODN) have anti-tumor activity when given at the tumor site. In this study, the authors asked
whether aerosol delivery of CpG-ODN might be more effective than systemic delivery against lung metastases in mice. It was
indeed more effective against metastases of immunogenic carcinoma cells. However, this was not the case against metastases
of poorly-immunogenic B16-melanoma cells. The results indicate that aerosol delivery may be a valuable, practical approach
to CpG therapy in the lung, but that tumor immunogenicity and tumor-induced immunosuppression are critical factors in its
success.
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each experiment, ﬂow cytometry using cellular inﬁltrates
from digested lungs of mice treated with Cl2MDP-liposomes
revealed that 70%–80% of alveolar macrophages were
depleted 72 hr after Cl2MDP injection, as compared to PBS-
liposome-treated mice (3 mice/group).
Statistical analysis
Analyses were performed using GraphPad Prism 5 (Graph-
Pad Software). For studies comparing differences between
two groups, the unpaired Student’s t test was used. For differ-
ences between more than two groups, statistical signiﬁcance
was determined using one-way Anova test, followed by a
Dunnet’s or Tukey’s post-test for comparison between
groups.
Results
Effects of CpG-ODN aerosolization in BAL fluid
The efﬁcacy of aerosolized CpG-ODN in reaching the lung
and inducing an immune response was evaluated in BAL
ﬂuid 24, 48 and 72 hr after aerosol treatment with 5 ml of
saline containing 0.5, 1.5 or 2.5 mg of oligonucleotide 1826
(5-10 FVB mice in the same aerosol box). Production of
IL-12p40, which has been shown to be the most increased
cytokine after i.n. CpG-ODN treatment,13 was threefold
higher in mice treated with 1.5 or 2.5 mg of CpG-ODN
versus saline-treated control mice and remained high even
after 48 and 72 hr, while no signiﬁcant increase in IL-12p40
was detected with the dose of 0.5 mg (Fig. 1a). No modula-
tion of IL12p40 concentration was observed in sera of mice
treated at the different doses of CpG-ODN as compared to
that in control mice (data not shown). A similar production
of IL-12p40 was observed in experiments using C57BL/6
mice (data not shown).
Proteomic analysis of a panel of pro-inﬂammatory cyto-
kines at 24, 48 and 72 hr after aerosol administration at the
selected dose of 1.5 mg CpG-ODN also revealed a signiﬁcant
increase in IL-1b and IFN-g (Fig. 1b) but no signiﬁcant
modulation of IL-2, IL-4, IL-5, IL12p70, TNF-a or IL-6 in
the BAL ﬂuids.
Analysis of DC cells (CD451CD11c1 F4/80-), which are
selectively recruited by i.n.-delivered CpG in the bronchoal-
veolar space,13 revealed no signiﬁcant changes in the percent-
age of these cells at 24, 48 and 72 hr in BAL ﬂuid recovered
from mice treated once with aerosolized CpG-ODN at 0.5,
1.5 or 2.5 mg/5 ml saline (data not shown); however,
repeated treatments with 1.5 mg CpG-ODN at intervals of
72–96 hr for 2 weeks induced a signiﬁcant increase in the
percentage of this population in BAL ﬂuid as compared to
control mice (Fig. 1c) and enhanced maturation of these cells,
as indicated by the signiﬁcant increase in expression levels of
the activation marker CD86 (Fig. 1d). This treatment sched-
ule also induced high production of IL-12p40 in BAL ﬂuid
(Fig. 1e).
Unlike i.n.-administered CpG-ODN, which induces
lung tissue inﬂammation associated with weight loss in
rodents,27–29 prolonged repeated treatments at intervals of
72-96 hr with 1.5 mg CpG-ODN aerosol for 3 weeks were
well tolerated. No effects on body weight and no histological
changes in the structure of lungs, as indicated by histopatho-
logical examination of hematoxylin and eosin-stained sections
of lung tissue, were observed in mice exposed to CpG-ODN
aerosolization (data not shown). Together, the results indicate
that aerosolized CpG-ODN can reach the bronchoalveolar
space in the lung and locally activate an innate immune
response without apparent signs of toxicity.
Anti-tumor activity of aerosolized CpG-ODN against
N202.1A mammary tumor cells
The efﬁcacy of CpG-ODN aerosolization versus i.p. adminis-
tration in controlling the growth of experimental lung metas-
tases was evaluated in mice bearing the immunogenic
N202.1A tumor, a mammary carcinoma overexpressing the
rat neu oncogene. FVB mice were injected i.v. with 3 3 105
N202.1A cells and, 72 hr later, treated at 72–96 hr intervals
for 3 weeks with aerosolized 5 ml saline containing 1.5 or 2.5
mg CpG-ODN (to treat up to 10 mice in the same aerosol
box) or with 20 mg/mouse CpG-ODN administered i.p. (in
200 ml saline). At 5 weeks after treatment, the number of
lung colonies was signiﬁcantly lower in mice treated with 1.5
or 2.5 mg CpG-ODN aerosolization (p< 0.001 1.5 mg CpG-
ODN vs. control; p< 0.05 2.5 mg CpG-ODN vs. i.p.), but not
in mice treated i.p. with CpG-ODN, as compared to controls
(Fig. 2a). Each i.p. CpG-ODN injection, but not aerosolized
CpG-ODN, induced transient weight loss (about 1 g) in mice
(data not shown).
To compare the immune effector cells inﬁltrations
induced in tumors by the TLR agonist through the two
administration routes, the experiment above was repeated
and lung inﬁltration of CD451 cells was evaluated by ﬂow
cytometry after enzymatic digestion of lung tissue at day 15
after tumor cell injection. Analysis of the FCSlowSSClow
fraction (Fig. 2b) revealed a signiﬁcantly increased percentage
of CD31CD41 T cells but no modulation of NK cells
(DX51CD3-) in the lung of mice receiving aerosolized
CpG-ODN as compared to untreated N202.1A tumor-bearing
mice, while i.p. administration induced a signiﬁcant increase
of NK cells but did not modulate the percentage of T cells
(CD31CD41 or CD31CD81). Thus, locally administered
CpG-ODN was more effective in promoting an expansion of
CD41 T cells in lungs bearing an immunogenic tumor,
whereas i.p. administration preferentially expanded NK cells.
Anti-tumor activity of aerosol CpG-ODN treatment in B16
melanoma tumors
As most primary lung tumors and frequently lung metastases
derived from other tumor histotypes in humans are only
weakly immunogenic, we compared the efﬁcacy of the two
administration routes against B16 murine melanoma, in
which protection is mediated by NK cells.30–32 Mice were
injected i.v. with 5 3 105 B16 cells and treated with 1.5 mg
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Figure 1. Immune effects of aerosolized CpG-ODN in BAL fluid. (a) IL-12p40 levels evaluated by ELISA in BAL of mice at 24 hr after aerosol
with CpG-ODN at different concentrations (left) and at different times after a single treatment with 1.5 mg of CpG-ODN (right). (b) IFN-g and
IL-1b levels evaluated by proteomic analysis in BAL collected 24, 48 and 72 hr after a single CpG-ODN aerosolization (1.5 mg). All values
(pg/ml) are expressed as mean6SE (5–6 mice/group). ***p<0.001, **p<0.01, *p<0.05 versus control, by one-way ANOVA followed by
Dunnet’s post-test. (c) A representative flow cytometric analysis of DC (identified as CD11c1F4/80- cells among CD451 cells after lympho-
cyte exclusion) in BAL after 4 CpG-ODN (1.5 mg) or saline aerosol treatments at intervals of 72–96 hr (left). Histogram on the right shows
the frequency of DC in 8–10 mice per group. **p<0.01, *p<0.05 versus control, by Student’s t test. (d) A representative flow cytometric
analysis of CD86 expression level, represented as mean fluorescence intensity (MFI) performed in the DC gate (as described in Panel c)
(left). Histogram on the right shows the CD86 MFI in the DC gate in 8–10 mice per group. **p<0.01, *p<0.05 versus control, by Student’s
t test. (e) IL-12p40 levels in BAL collected at 24 hr after the last of four treatments at 72–96 hr intervals with aerosolized CpG-ODN (1.5
mg). Values (pg/ml) are expressed as mean6SE (5–6 mice/group). ***p<0.001 versus control, by Student’s t test.
Figure 2. Effect of aerosol or intraperitoneal administration of CpG-ODN on N202.1A experimental lung metastases. (a) Number of macro-
scopic lung metastases at 5 weeks after i.v. injection of N202.1A mammary carcinoma cells in mice untreated or treated with CpG-ODN i.p.
or by aerosol (9 mice/group). *p<0.05; ***p<0.001 by one-way ANOVA followed by Tukey’s post-test. (b) A representative flow cytometric
analysis of immune infiltrate of lungs of mice at 2 weeks after i.v. injection with N202.1A tumor cells untreated or treated with CpG-ODN
aerosol or i.p. NK cells were identified as DX51CD3-, while CD41 and CD81 T cells were identified in CD31 gated cells (among CD451
FSClowSSClow-gated cells). Histograms show the frequency of different populations in 5 mice per group (mean6SE). ***p<0.001 by one-
way ANOVA followed by Dunnet’s post-test.
aerosolized or i.p.-administered CpG-ODN (20 mg/mouse) at
72–96 hr intervals for 3 weeks, beginning 72 hr after tumor
cell injection. A third group of mice was left untreated as a
control for lung tumor colonization. In contrast with the
N202 tumor model, mice treated with CpG-ODN aerosol
showed no signiﬁcant reduction in the number of lung me-
tastases at 5 weeks, while i.p. CpG-ODN administration
induced signiﬁcant protection (p< 0.0001 CpG-ODN i.p. vs.
control) (Fig. 3a). Flow cytometric analysis of CD451
immune effector cells in treated or untreated mice after
enzymatic digestion of lung tissues at day 15 after tumor
injection indicated that neither aerosol nor i.p. administration
expanded CD31CD41 and CD31CD81 T cells in this
tumor model, whereas i.p., but not aerosol CpG-ODN, treat-
ment induced a strong increase in the percentage of NK cells
(Fig. 3b). The increased percentage of NK cells in the lung
induced by systemic treatment did not appear to reﬂect spe-
ciﬁc tumor-induced recruitment but rather an increased
number of CpG-induced circulating NK cells, because a simi-
lar expansion of DX51CD3- cells was detected in lung as
well as in spleen and blood of tumor-free mice after i.p.
injection of CpG-ODN (23.7%6 1.7% in i.p.-treated vs.
12.5%6 0.9% in untreated mice in the lung; 4.8%6 0.2%
and 5.3%6 0.5 % in i.p.-treated vs. 3.4%6 0.1 % and
2.7%6 0.3 % in untreated mice in the spleen and blood,
respectively; 4 mice/group).
Alveolar macrophages as suppressive immune effectors in
lung infiltrate of metastases-bearing mice
With progressive tumor growth, resident pulmonary alveolar
macrophages, which are the most abundant inﬂammatory
cells in the lungs, frequently shift their polarization to the
M2 phenotype and exert suppressive activity on T and NK
cells.33–36 Double immunoﬂuorescence to detect the presence
of macrophages (CD681) secreting IL-10, a marker of the
M2 phenotype, in lungs of mice injected i.v. with B16 or
N202.1A tumor cells revealed a high number of CD681 cells
secreting IL-10 in B16 tumor-bearing mice, whereas only low
number of CD681/IL-101 double-positive cells was detected
in the lungs of N202.1A tumor-bearing mice (Fig. 4). Thus,
the inability of aerosol CpG-ODN to induce effective
immune activation in B16 tumor-bearing lungs might be due
to a strong immunosuppressive activity established by alveo-
lar macrophages in this tumor microenvironment, raising
the possibility that depletion of macrophages might allow
NK expansion induced by aerosol CpG-ODN in this tumor
model. Having determined empirically that a single i.t.
injection of clodronate encapsulated liposomes greatly
reduces the percentage of alveolar macrophages (% of
CD451CD11c1CD11b- in digested lungs: 2.6661.3 in
Cl2MDP liposome-treated versus 11.1762.3 in liposome-
treated mice evaluated 72 hr after injection), consistent with
previous data,37 we tested the effect of macrophage depletion
on aerosol CpG-ODN-induced NK cell expansion in four
groups of mice (5 mice/group) injected i.v. with 5 3 105 B16
cells and, after 96 hr, injected i.t. with 100 ml of Cl2MDP-lip-
osome (three groups) or 100 ml of control liposome (the
fourth group). After 24 hr, two groups of mice given
Cl2MDP liposomes started the treatment with aerosol (1.5
mg) or i.p. (20 mg) CpG-ODN for 4 days/week for 2 weeks,
while the third and fourth groups treated with Cl2MDP lipo-
some and control liposome, respectively, received no CpG-
ODN. Analysis of the phenotype and composition of the
immune cell inﬁltrate in the lung at 24 hr after the last CpG-
ODN treatment (Fig. 5a) indicated that in the absence of res-
ident macrophages, aerosol CpG-ODN treatment did indeed
induce signiﬁcant NK cell expansion in B16 tumor-bearing
lungs. In these lungs, the increased percentage of DX51CD3-
cells gated in the CD451 population corresponded to a sig-
niﬁcant decrease of the percentage of CD31 cells. Mice
treated with clodronate alone revealed a reduced percentage
of alveolar macrophages without modiﬁcation in the percent-
age of NK and CD31 cells as compared to mice treated with
control liposomes.
Anti-tumor activity of aerosol CpG-ODN treatment against
B16 melanoma cells in clodronate-treated mice
To determine whether the changes in cellular immune lung
inﬁltrates induced by CpG-ODN aerosol in clodronate-
treated B16 tumor-bearing mice would lead to improved
anti-tumor activity, six groups of mice were injected i.v. with
B16 cells and, after 96 hr, injected i.t. with Cl2MDP lipo-
somes (three groups) or control liposome (three groups) but
started on treatment with CpG-ODN aerosol (one group
Cl2MDP liposome-treated and one group liposome-treated)
or i.p. (one group Cl2MDP liposome-treated and one group
liposome-treated) at day 5 (120 hr) after tumor injection to
allow resident macrophage depletion before treatment. Treat-
ment was continued for 4 days/week for 3 weeks. The
remaining two groups of Cl2MDP liposome- and control lip-
osome-treated mice received no CpG-ODN. Aerosol CpG
therapy in macrophage-depleted mice induced a signiﬁcant
reduction in the number of lung metastases, as observed 5
weeks after tumor injection (Fig. 5b), whereas macrophage
depletion did not modify the efﬁcacy of i.p. treatment. More-
over, clodronate-induced macrophage depletion per se did
not reduce tumor growth, as the number of lung metastases
in Cl2MDP liposome- versus control liposome-treated mice
did not differ signiﬁcantly. These data indicate that depletion
of resident macrophages in tumor-bearing mice allows CpG
aerosol therapy to stimulate a local immune response that
confers signiﬁcant protection from lung metastases.
As Ly6G1 granulocytic polymorphonuclear neutrophil
subsets of myeloid-derived suppressor cells (PMN-MDSC)
reportedly impair NK cell development speciﬁcally38–40 and
as cross-talk between tumor-associated macrophages and
MDSCs has been shown to sustain and exacerbate immune
suppression in the tumor microenvironment,41 we tested
whether this population was also involved in preventing NK
cell expansion induced by CpG-ODN aerosol. Four groups of
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Figure 3. Effect of aerosol or intraperitoneal administration of CpG-ODN against B16 experimental lung metastases. (a) Number of macro-
scopic lung metastases at 5 weeks after i.v. injection of B16 melanoma cells in mice untreated (10 mice) or treated with CpG-ODN aerosol
(10 mice) or i.p. (8 mice). *p<0.05; ***p<0.001 by one-way ANOVA followed by Tukey’s post-test. (b) A representative flow cytometric
analysis of immune infiltrate of lungs of mice at 2 weeks after i.v. injection with B16 tumor cells untreated or treated with CpG-ODN aerosol
or i.p. NK cells were identified as DX51CD3-, while CD41 and CD81 T cells were identified in CD31 gated cells (among CD451 FSClowS-
SClow-gated cells). Histograms on the right show the frequency of different populations in 5 mice per group (mean6SE). ***p<0.001 by
one-way ANOVA followed by Dunnet’s post-test.
mice (5 mice/group) were injected with B16 cells as above
and, 96 hr later, treated every 72–96 hr with the Ly6G-spe-
ciﬁc mAb (1A8), which recognizes and depletes Ly6Ghigh
neutrophilic populations, or with isotype control. At 24 hr
after the ﬁrst mAb treatment, two groups of mice started the
treatment with aerosolized CpG-ODN (1.5 mg) for 4 days/
week for 2 weeks, while the other two groups of antibody-
treated mice received no CpG-ODN. 1A8 mAb treatment
induced a strong depletion of granulocytic MDSC, identiﬁed
as Ly6GhighCD11b1 cells not expressing or expressing low
levels of the Ly6C marker, but in the lungs of these depleted
mice, CpG-ODN aerosol therapy induced only a slight
expansion of NK cells (Supporting Information Fig. 1). These
results suggest that granulocytic MDSC do not play a major
role in macrophage-induced immunosuppression.
Discussion
Our study to explore aerosol administration as a promising
route for delivery of CpG-ODN to the murine lung showed
that aerosolized CpG-ODN reaches the bronchoalveolar space
and can activate a local immune response, as indicated by
the increased levels of IL-12p40, IFN-g and IL-1b and the
recruitment and maturation of DC in BAL ﬂuid. Consistent
with previous ﬁndings that alveolar macrophages respond to
CpG-ODN with production of IL-12p40 but not IL-12p70,13
we detected no production of IL-12p70 in BAL ﬂuids, which
contain alveolar macrophages almost exclusively. No signs of
apparent toxicity, evaluated as body weight loss and as histo-
logical changes in lung architecture, were observed after
repeated CpG-ODN aerosol administration, in contrast with
the adverse effects reported in mice receiving CpG-ODN i.n.
or i.t.27–29
The anti-tumor activity of aerosol-delivered CpG-ODN
was evaluated in two murine tumor models with different
characteristics and behavior: the mammary carcinoma
N202.1A is highly immunogenic due to overexpression of the
heterologous rat neu oncogene,25 while the B16 melanoma is
poorly immunogenic and reportedly expresses very low levels
of MHC I molecules.42 These two tumors also differ in their
sensitivity to immune effectors, with the neu-expressing
mouse mammary tumor sensitive to cytotoxic activity of T
but not NK cells,43 while NK cells are required to counteract
the growth of B16 melanomas.30–32 We observed that while
N202.1A tumors in the lung induced a low level of CD681
macrophages secreting IL-10, B16 melanoma cells strongly
promoted the presence of double-stained CD681IL-101
Figure 4. Analysis of IL-10-secreting macrophages in tumor-bearing lungs. Immunofluorescence analysis of sections of lung tissue collected
4 weeks after i.v. injection of B16 melanoma cells or N202.1A mammary carcinoma cells and double-stained for CD68 (red) and IL-10
(green). Representative images show single and double (merged) staining of formalin-fixed, paraffin-embedded samples. Immunohistochem-
ical staining shows CD681 cells populating alveolar spaces of normal lungs and lungs with either B16 or N202.1A tumor metastases. Origi-
nal magnification 3400, 3200 inset magnification.
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cells, suggesting the potential of the latter model to induce an
immunosuppressive microenvironment. Accordingly, Gil-Ber-
nabe` et al.44 have recently observed in lungs from mice
injected with B16 melanoma cells the selective recruitment of
CD681 macrophages essential for tumor cell survival. These
observations are consistent with studies showing that alveolar
macrophages in the presence of some growing tumors
become immunosuppressive,33,35 i.e., develop M2 tumor-asso-
ciated macrophages, which play a role in the progression and
prognosis of lung cancer.45,46 Depending on their relative im-
portance, any or all of these differences might underlie the
different results observed in the two models.
In the immunogenic N202.1A model, aerosol-delivered
CpG-ODN induced the preferential expansion of CD41
cells and was more efﬁcacious than i.p. administration in
control lung metastases, suggesting that the local addition
of a TLR agonist might help the immune system recognize
and eliminate tumor. Our preliminary experiments demon-
strating a complete cure of N202.1A lung metastases in 5
of 10 mice treated with aerosol 15 mg CpG-ODN/5 ml
Figure 5. Effect of clodronate-induced macrophage depletion on aerosol or intraperitoneal CpG-ODN treatment of B16 lung metastases-bear-
ing mice. (a) Frequency of CD31 T cells (among CD451 FSClowSSClow-gated cells), NK cells (DX51CD3- among CD451 FSClowSSClow-
gated cells) and alveolar macrophages (F4/801 CD11b- CD11c1 among CD451 gated cells) evaluated by flow cytometric analysis of
immune infiltrate of lungs of mice at 2 weeks after i.v. injection with B16 tumor cells and i.t. treatment 96 hr later with clodronate encapsu-
lated liposomes or PBS-liposomes. At 24 hr after liposome treatment, two groups of clodronate-treated mice started treatment with CpG-
ODN i.p. or aerosol. Histograms represent pooled data from 5 mice per group (mean6SE). ***p<0.001 by one-way ANOVA followed by
Dunnet’s post-test. (b) Number of macroscopic lung metastases at 5 weeks after i.v. injection of B16 melanoma cells in mice injected i.t
with PBS-liposomes alone (12 mice), clodronate encapsulated liposomes alone (8 mice), PBS-liposomes followed by aerosol (6 mice) or
i.p. (7 mice) CpG-ODN treatment, or clodronate encapsulated liposomes followed by aerosol (12 mice) or i.p. (14 mice) CpG-ODN treatment.
*p<0.05; ***p<0.001 by one-way ANOVA followed by Tukey’s post-test.
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saline without reduction of weight suggest the promise of
increasing the dose of aerosolized CpG-ODN to achieve
complete protection in this immunogenic model. In con-
trast, i.p. delivery of CpG-ODN in the B16 melanoma
model stimulated a strong expansion of NK cells and
induced signiﬁcant protection against lung metastases, while
CpG aerosol treatment failed to modify the number of NK
cells in lung and did not confer signiﬁcant protection.
Depletion of lung macrophages by liposome encapsulated
clodronate, a bisphosphonate compound,47 allowed aerosol-
ized CpG-ODN to expand NK cells and reduce the number
of lung metastases. Aerosol inhalation to deliver Cl2MDP-
liposomes to the lung has been recently reported,48 raising
the possibility of aerosolized bisphosphonates in clinical use.
In contrast, depletion of the MDSC granulocytic component
by anti-Ly6G antibody induced only a slight increase in NK
cell expansion, excluding major involvement of this compo-
nent in immunosuppression. Thus, other direct or indirect
mechanisms, such as those induced by the production of
suppressive cytokines as well as prostaglandin E, hydrogen
peroxide and superoxide by alveolar macrophages that
support the maintenance of the suppressive microenviron-
ment33 might be involved in inhibition of CpG local
activity.
Several studies have reported the superior anti-tumor
effect of CpG administered directly rather than systemically
into the tumor in both immunogenic or nonimmunogenic
tumor models, since CpG-ODN can activate both innate and
adaptive immune responses at the tumor site.6–9 Our results
indicate that this is not true for tumors growing in the lung,
where both tumor immunogenicity and the tumor-induced
immunosuppressive environment are critical factors in the
success of CpG therapy. Thus, different administration routes
might be required for different tumors.
The composition of immune cells localized to the lung likely
reﬂects the degree to which the immune system is subverted by
the tumors, consistent with the reported prognostic value of
characterization of immune inﬁltrate in the lung in non-small
cell lung carcinoma and in lung adenocarcinoma.49,50 Evalua-
tion of the patient lung immune status through analysis of BAL
composition50 might provide a noninvasive means of routinely
sampling the immune environment of the lung to deﬁne the
best immunotherapeutic strategy.
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